$3.5 trillion. That's Microsoft's market capitalization as of Wednesday, ranking behind Google parent Alphabet ($3.8 trillion), Apple ($4.2 trillion) and Nvidia ($4.3 trillion), respectively.

Tyler Technologies, Inc. (TYL) Presents at UBS Global Technology and AI Conference 2025 Transcript

Kimberly-Clark Corporation (KMB) Presents at Morgan Stanley Global Consumer & Retail Conference 2025 Transcript

Arcus Biosciences, Inc. (RCUS) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Payoneer Global Inc. (PAYO) Presents at UBS Global Technology and AI Conference 2025 Transcript

Elanco Animal Health Incorporated (ELAN) Presents at Evercore 8th Annual Healthcare Conference Transcript

ODFL's revenue per day fell 4.4% year over year in November 2025, owing to a 10% decrease in LTL tons per day, partially offset by an increase in LTL revenue per hundredweight.

RYAAY posts a 6% jump in November traffic with 13.8M passengers, steady load factor, and a lifted fiscal 2026 outlook on strong travel demand.

U.S. President Donald Trump met with chip giant Nvidia CEO Jensen Huang on Wednesday to discuss export controls, a CBS News reporter said in a post on X.

NEW YORK, NY / ACCESS Newswire / December 3, 2025 / A silent bomb is ticking inside the global gold market, and the West is standing directly over it. The world's most valuable commodity has become the easiest material for sanctioned regimes to move, disguise, and inject into Western supply chains.

RESTON, Va. , Dec. 3, 2025 /PRNewswire/ -- The board of directors of General Dynamics (NYSE: GD) today declared a regular quarterly dividend of $1.50 per share on the company's common stock, payable February 6, 2026, to shareholders of record on January 16, 2026.

NEW YORK and NEW ORLEANS , Dec. 3, 2025 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

Shares of American Bitcoin Corp., the crypto miner co-founded by Eric Trump, lost more than half of their value in less than 30 minutes on Tuesday, triggering repeated trading halts. Monique Mulima reports on Bloomberg Television.

Why this analyst agrees with Michael Burry in Tesla's overvaluation.

NEW YORK--(BUSINESS WIRE)--Oliver Wyman, a global leader in management consulting and a business of Marsh McLennan (NYSE:MMC), and the Association of Equipment Manufacturers (AEM) today unveiled findings from a joint study on the state of the North America's industrial goods sector, focusing on construction and agricultural manufacturing. The State of the Industrial Goods North America, Non-Road Edition, reveals declining sentiment among equipment manufacturers in the face of tariff unpredictab.

NEWARK, NJ, Dec. 03, 2025 (GLOBE NEWSWIRE) -- IDT Corporation (NYSE: IDT), a global provider of fintech and communications services, commented on the decision issued today by the Delaware Supreme Court affirming the Court of Chancery's post-trial decision dismissing all claims against IDT and finding no harm to Straight Path Communications Inc. (“Straight Path”) shareholders.

NEW YORK and NEW ORLEANS , Dec. 3, 2025 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

Capricor Therapeutics, Inc. (NASDAQ: CAPR) stock soared on Wednesday after the company announced positive topline data from the Phase 3 HOPE-3 trial for its lead cell therapy candidate, deramiocel.

RTX is a core US defense sector holding, benefiting from robust demand, record backlog, and strong double-digit revenue and earnings growth. RTX's premium valuation is justified by sustained geopolitical tensions, multi-year defense spending increases, and dominant positioning in critical US and allied defense programs. I assign RTX a Buy rating with a $193 target, reflecting 13.2% upside, supported by conservative DCF assumptions and alignment with Wall Street consensus.

Trevi Therapeutics (TRVI) is initiated with a "Buy" rating, driven by its lead asset Haduvio's advancement toward phase 3 testing for chronic cough in IPF. Company's Haduvio demonstrated statistically significant efficacy in phase 2b CORAL study [IPF] and phase 2a RIVER [RCC], with a differentiated dual central/peripheral mechanism of action. The company is well-capitalized, with $194.9M in cash and a projected runway into 2028, supporting upcoming pivotal trials.